Effects of aerobic and resistance exercises on circulating apelin-12 and apelin-36 concentrations in obese middle-aged women: a randomized controlled trial

What Was Tested

The paper reports a study of Apelin, published as a randomized controlled trial.

However, there is still a lack of evidence on the association of apelin concentration with different exercise types in middle-aged obese women This study aimed to investigate the effects of 8 weeks of aerobic and resistance exercises on apelin-12 and apelin-36 levels and thereby verify the effects of different exercise types in obese, middle-aged women.

Why It Was Studied

In obesity, adipokines secreted from adipose tissue induce inflammation, causing adverse effects.

No. 1040917-201,506-BR-153-04 , Clinical Research Information Service (CRIS), Republic of Korea (05 October 2018, retrospectively registered).

Who Took Part

PubMed indexes the participants as middle-aged adults, both men and women.

Subjects were selected and allocated to the aerobic exercise, resistance exercise, or no exercise group by block randomization.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Apelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Body weight, body fat, and body mass index were measured by bioelectrical impedance analysis.

Analysis of variance, the t-test, and Tukey's post-hoc test were performed.

What Was Measured

Topics PubMed links to this paper include Apelin, Body Composition, Body Mass Index, Exercise, Exercise Therapy, Intercellular Signaling Peptides and Proteins and Metabolic Syndrome.

The authors tagged it with the keywords Aerobic exercise, Apelin-12, Apelin-36, Obese middle-aged women and Resistance exercise.

What This Means in Plain Language

The paper is a randomized study of Apelin.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (BMC women's health), a journal based in England.

More context: the Apelin compound page, all human trials.